Brief: Palatin Technologies announces initiation of patient recruitment for Phase 2 Clinical Study Evaluating Oral Pl8177 for treatment of ulcerative colitis
08/09/2022 12:33
Sept 8 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN ANNOUNCES INITIATION OF PATIENT RECRUITMENT FOR
PHASE 2
CLINICAL STUDY EVALUATING ORAL PL8177 FOR TREATMENT OF
ULCERATIVE COLITIS
* PALATIN TECHNOLOGIES INC - ORAL PL8177 MAY PROVIDE A SAFE
AND
TOLERABLE TREATMENT OPTION FOR ULCERATIVE COLITIS PATIENTS
Source text for Eikon: ID:nPncdHZfYa
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity